Intravenous thrombolysis for suspected ischemic stroke with seizure at onset by TRISP Collaborators et al.
 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ana.25582 
 
Intravenous Thrombolysis for Suspected Ischemic Stroke with Seizure at Onset 
 
Alexandros A. Polymeris, MD1; Sami Curtze, MD, MSc, PhD2; Hebun Erdur, MD3; Christian 
Hametner, MD4; Mirjam R. Heldner, MD, MSc5; Adrien E. Groot, MD6; Andrea Zini, MD7; 
Yannick Béjot, MD, PhD8; Annina Dietrich9; Nicolas Martinez-Majander, MD, MSc2; Regina 
von Rennenberg, MD3; Christoph Gumbinger, MD4; Sabine Schaedelin, MSc10; Gian Marco 
De Marchis, MD, MSc1; Sebastian Thilemann, MD1; Christopher Traenka, MD1,11; Philippe A. 
Lyrer, MD1; Leo H. Bonati, MD1; Susanne Wegener, MD9; Peter A. Ringleb, MD4; Turgut 
Tatlisumak, MD, PhD2,12; Christian H. Nolte, MD3; Jan F. Scheitz, MD3; Marcel Arnold, MD5; 
Daniel Strbian, MD, MSc, PhD2, Paul J. Nederkoorn, MD, PhD6; Henrik Gensicke, MD1,11 and 
Stefan T. Engelter, MD1,11 for the TRISP Collaborators 
1Department of Neurology and Stroke Center, University Hospital Basel and University of 
Basel, Basel, Switzerland 
Department of Neurology, Charité-Universitaetsmedizin Berlin, Berlin, Germany 
4Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany 
5Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, 
Switzerland 
6Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, the 
Netherlands 
7IRCCS Istituto di Scienze Neurologiche di Bologna,  Department of Neurology and Stroke 
Center, Maggiore Hospital, Bologna, Italy 
8University Hospital and Medical School of Dijon, University of Burgundy, France 
9Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland 
10Clinical Trial Unit, Department of Clinical Research, University Hospital Basel and 
University of Basel, Basel, Switzerland 
11Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix 
Platter; University of Basel, Basel, Switzerland 
12Department of Neurology, Sahlgrenska University Hospital and Department of Clinical 
Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University 
of Gothenburg, Gothenburg, Sweden  
This article is protected by copyright. All rights reserved.
  
 
Correspondence to:  
Alexandros A. Polymeris 
Department of Neurology and Stroke Center 
University Hospital Basel and University of Basel 
Petersgraben 4, 4031 Basel, Switzerland 
Alexandros.Polymeris@usb.ch 
Running Head: IVT for Suspected Stroke with Seizure at Onset 
Keywords: intravenous thrombolysis, seizure at onset, treatment outcome 
Characters in Title: 76  
Characters in Running Head: 46  
Word Count Abstract: 244/250 
Word Count Manuscript: 4,094/4,500 (Introduction: 395/500, Discussion: 986/1,500) 
References: 46/50 
Figures: 1 
Tables: 2, Supplemental tables: 5  
This article is protected by copyright. All rights reserved.
  
 
Abstract 
 
Objective 
Seizure at onset (SaO) has been considered a relative contraindication for intravenous 
thrombolysis (IVT) in patients with acute ischemic stroke, although this appraisal is not 
evidence-based. Here, we investigated the prognostic significance of SaO in patients treated 
with IVT for suspected ischemic stroke.  
 
Methods 
In this multicenter, IVT-registry-based study we assessed the association between SaO and 
symptomatic intracranial hemorrhage (sICH, ECASS-II definition), 3-month mortality and 3-
month functional outcome on the modified Rankin Scale (mRS) using unadjusted and 
adjusted logistic regression, coarsened exact matching and inverse probability weighted 
analyses.  
 
Results 
Among 10,074 IVT-treated patients, 146 (1.5%) had SaO. SaO patients had significantly 
higher NIHSS and glucose on admission and more often female sex, prior stroke and prior 
functional dependence than non-SaO patients. In unadjusted analysis, they had generally 
less favorable outcomes. After controlling for confounders in adjusted, matched and weighted 
analyses, all associations between SaO and any of the outcomes disappeared, including 
sICH (odds ratio [OR]unadjusted 1.53 [95% confidence interval: 0.74,3.14], ORadjusted 
0.52[0.13,2.16], ORmatched 0.68[0.15,3.03], ORweighted 0.95[0.39,2.32]), mortality (ORunadjusted 
1.49[1.00,2.24], ORadjusted 0.98[0.5,1.92], ORmatched 1.13[0.55,2.33], ORweighted 1.17[0.73,1.88]) 
and functional outcome (mRS≥3 / ordinal mRS: ORunadjusted 1.33[0.96,1.84] / 1.35[1.01,1.81], 
ORadjusted 0.78[0.45,1.32] / 0.78[0.52,1.16], ORmatched 0.75[0.43,1.32] / 0.45[0.10,2.06], 
ORweighted 0.87[0.57,1.34] / 1.00[0.66,1.52]). These results were consistent regardless of 
whether patients had an eventual diagnosis of ischemic stroke (89/146) or stroke mimic 
(57/146 SaO patients).  
 
Interpretation 
SaO was not an independent predictor of poor prognosis. Withholding IVT from patients with 
assumed ischemic stroke presenting with SaO seems unjustified.   
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Introduction 
Intravenous thrombolysis (IVT) is effective and safe in selected patients with acute ischemic 
stroke.1 A seizure at onset (SaO) of an acute stroke syndrome is uncommon, but has 
traditionally been considered as a relative contraindication for IVT.2-4  
This traces back to the explicit exclusion of patients with SaO from the pivotal National 
Institute of Neurological Disorders and Stroke (NINDS) randomized controlled trial5, as well 
as from the vast majority of subsequent IVT trials for acute ischemic stroke1. The rationale for 
this was that neurological deficits associated with seizures usually reflect a transient postictal 
phenomenon mimicking a stroke and that such patients should not be exposed to an 
unnecessary bleeding risk.4 However, seizures do also occur at the onset of an actual acute 
ischemic stroke.6 Since such patients were excluded from the trials, there is currently only 
weak evidence for the use of IVT in stroke patients with SaO. 
The latest AHA/ASA Guidelines (2018) removed SaO from the IVT contraindications list and 
make a moderate recommendation for IVT in patients with SaO “if evidence suggests that 
residual impairments are secondary to stroke and not a postictal phenomenon”.7 However, 
differentiating between these two entities in the acute phase, when time is precious, is 
challenging, especially in the absence of advanced imaging.8-11 Observational data suggest 
that IVT seems to be safe in patients with stroke mimics, of whom several had had seizures 
with postictal symptoms but without acute stroke.12-15 As these diagnoses were usually made 
retrospectively, the applicability in the acute management of patients presenting with SaO is 
limited. Furthermore, the prognostic importance of a seizure at presentation is also unclear 
among those IVT-treated patients who eventually had a verified acute ischemic stroke. For 
stroke physicians considering IVT in patients with suspected ischemic stroke and SaO, more 
data about safety and effectiveness are needed to inform their decisions in the acute phase.  
With these considerations in mind, we investigated the prognostic significance of SaO in 
patients treated with IVT for assumed ischemic stroke. This included both patients who were 
eventually diagnosed with an acute stroke and those with a final diagnosis of a stroke mimic. 
Reflecting clinical practice, we analyzed both groups together in the main analysis. In 
ancillary analyses we assessed for interaction between final diagnosis and prognostic 
significance of SaO and repeated all analyses in the subgroup of patients with eventual 
diagnosis of ischemic stroke.  
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Methods 
Study design, patient population and data collection 
For this study, we pooled data on prospectively registered, consecutive patients with 
suspected acute ischemic stroke treated with IVT alone or IVT followed by endovascular 
treatment (EVT) from 9 European stroke centers within the ThRombolysis in Ischemic Stroke 
Patients (TRISP) Collaboration. The detailed methodology of TRISP has been previously 
published.16 In short, data were collected locally at each TRISP center using a standardized 
form with predefined parameters and were pooled and analyzed at the TRISP center Basel. 
This study had been submitted to the ethics committee in the leading center Basel. The 
committee had no ethical concerns and waived the necessity to obtain informed consent from 
individual patients (Ethics Committee of Northwest and Central Switzerland UBE-15/118). 
The requirement for local ethics approval differed between participating centers, and 
approval was obtained if required. The list of TRISP centers participating in this study 
including number of patients contributed by each center and time period of data collection, as 
well as the complete list of all TRISP centers and collaborators are given in Supplemental 
Table 1.  
The main parameter of interest for this study was presence versus absence of SaO. SaO 
was defined adapting previously reported definitions6, 17 as any clinically evident seizure, as 
observed by witnesses or medical providers, from stroke onset to IVT (i.e., not later than the 
end of the IVT infusion). Patients with missing information on presence or absence of SaO 
were excluded from the study.  
The following baseline TRISP parameters were used: age, sex, vascular risk factors 
according to predefined criteria16, prior stroke, prior antithrombotic treatment (antiplatelets 
and/or anticoagulants), prior functional dependence (defined as pre-stroke modified Rankin 
Scale (mRS) ≥ 3), National Institutes of Health Stroke Scale (NIHSS) score on admission, 
estimated glomerular filtration rate (eGFR) according to the Chronic Kidney Disease 
Epidemiology Collaboration formula18 and glucose on admission, onset-to-treatment time, 
treatment with IVT alone or IVT followed by EVT, presence or absence of early hypodensity 
on initial computed tomography (CT) scan (as in prior research18, added post hoc) and final 
diagnosis of ischemic stroke or stroke mimic. Stroke mimics were labeled as such when any 
final diagnosis other than stroke was made by the patients' treating physicians after exclusion 
of an ischemic cause of the stroke-like symptoms based on clinical examinations and 
neuroimaging findings, as previously described.12, 14  
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Outcome measures were: (i) symptomatic intracranial hemorrhage (sICH), according to the 
European Cooperative-Acute-Stroke-Study-II (ECASS-II) definition19, (ii) all-cause mortality at 
3 months and (iii) functional outcome on the mRS at 3 months. As previously described16, the 
3-month outcomes were assessed during outpatient visits or with postal questionnaires or 
telephone calls with patients, patients’ relatives and/or general practitioners as applicable.  
For the SaO patients we reviewed the detailed medical charts post hoc to provide a full 
clinical and radiological characterization of these cases. We systematically collected the 
following parameters: type of seizure (according to the 2017 International League Against 
Epilepsy classification20), timing of seizure with regards to hospital admission and IVT, 
seizure duration, treatment of the seizure, seizure recurrence during hospital stay, 
information on neuroimaging modalities used before IVT and thereafter and neuroimaging 
findings (including sICH according to the ECASS-III definition21), presence or absence of 
potentially confounding factors22, 23 including electrolyte abnormalities, hypoglycemia, chronic 
ischemic brain lesions, intracranial tumors, brain vascular malformations, 
meningoencephalitis, endocarditis, cerebral venous thrombosis, history of traumatic brain 
injury or intracranial hemorrhage, alcohol or drug abuse, history of seizures or epilepsy, prior 
use of antiepileptic drugs and benzodiazepines, dementia or other neurodegenerative 
disease, multiple sclerosis or other neuroinflammatory disease and psychiatric or 
neurodevelopmental disorders. For the SaO patients with a final diagnosis of stroke mimic we 
also collected the cause to which the seizures were finally attributed.  
Statistical analyses 
We used descriptive statistics to present the baseline data and the outcome measures. For 
continuous variables, the mean and standard deviation (SD) or, in case of skewed data, the 
median and interquartile range (IQR) were used. We present categorical variables as count 
and frequency. We report the rate of missing values for all variables.  
We compared baseline data between patient subgroups using the χ2 test for categorical 
variables and the t-test or Mann-Whitney U test as appropriate for continuous variables. A p-
value < 0.05 was considered statistically significant. 
To assess the association between SaO and the respective outcome measures we used the 
following methods: 
(i) Unadjusted logistic regression 
(ii) Logistic regression adjusted for confounding by the following potentially outcome-
modifying parameters, as in prior research18, 24: age, sex, NIHSS on admission, prior 
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antithrombotic treatment, glucose and eGFR on admission, EVT in addition to IVT, onset-
to-treatment time, prior dependence and prior stroke. Missing values in these variables 
were imputed using five multiple imputations according to van Buuren and Groothuis-
Oudshoorn.25 
(iii) Matched analysis using coarsened exact matching. With this monotonic imbalance 
bounding matching method,26 patients with and without SaO were matched using all 
patients who had at least one matching partner. When several patients qualified as 
matching partners, they were weighted accordingly to avoid overrepresentation. In the 
matching model, the number of variables was reduced to the variables with the most 
imbalance in order to maintain enough matches.  Thus, the variables age, sex, NIHSS, 
glucose and eGFR on admission, prior stroke and final diagnosis of ischemic stroke or 
stroke mimic were included in the model. For the matching process, continuous variables 
were converted to categorical using 15 cut-off points according to Sturges’ rule. In case 
of missing values, an additional category labeled “missing values” was introduced in the 
variables included in the matching model. The matched data were then fit in a univariable 
logistic model as in (i).  
(iv) Inverse probability weighted analysis. For this analysis, the conditional probability of SaO 
was estimated for each patient using a logistic model with SaO as the outcome variable 
and the following parameters as independent variables: age, sex, NIHSS on admission, 
prior antithrombotic treatment, glucose and eGFR on admission, EVT in addition to IVT, 
onset-to-treatment time, prior stroke and final diagnosis of ischemic stroke or stroke 
mimic. The inverse probability weight (IPW)27, 28 was then calculated for each patient, and 
by multiplying the IPW by the unconditional probability of SaO (derived by a logistic 
model with SaO as outcome and an intercept only, without covariates28, 29), the stabilized 
IPW was calculated. The stabilized IPW was finally included in the adjusted logistic 
model described in (ii), and robust standard errors were used for the confidence intervals 
of this weighted analysis. In the models used to estimate the IPW, as well as in the 
weighted logistic model, missing values for the covariates were imputed using single 
imputation. Thereby the mean was imputed for continuous variables and the mode (i.e., 
the most common category) for categorical variables. 
For each method (i) – (iv), the model-based odds ratio (OR) estimate, 95% confidence 
interval (CI) and p-value are presented. 
To investigate potential differences in the prognostic significance of SaO in patients with a 
final diagnosis of ischemic stroke compared to those with a final diagnosis of stroke mimic, 
we performed the following ancillary analyses:  
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(a) We repeated the adjusted logistic regression analyses described in (ii) with the addition 
of the covariate “final diagnosis” and the interaction term “SaO * final diagnosis” in the 
model.  
(b) We repeated all analyses (i) – (iv) described above in the subgroup of patients with a 
final diagnosis of ischemic stroke (thereby excluding patients with a final diagnosis of 
stroke mimic and without using the covariate final diagnosis in these models). Repeating 
the analyses in the subgroup of patients with a final diagnosis of a stroke mimic was not 
possible due to the low number of patients and outcomes.  
The analyses described above were performed for all study outcomes including sICH, 
mortality at 3 months and mRS at 3 months both as a dichotomized binary variable (defining 
poor functional outcome as mRS ≥ 3) and as an ordinal variable with 7 levels (mRS 0 – 6). 
For the latter, the analyses were performed using proportional odds logistic models (i.e., shift 
models). Finally, as an ancillary analysis we repeated the unadjusted and adjusted logistic 
regression analyses (i) and (ii) for the outcome mRS on survivors only, after excluding 
patients with mRS = 6. Missing values in the outcome measures were imputed using five 
multiple imputations25 for the unadjusted and adjusted logistic regression analyses (i) and (ii), 
but not for the matched and weighted analyses (iii) and (iv). 
All analyses were performed in R version 3.5.0 (Foundation for Statistical Computing, 
Vienna, Austria).  
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Results 
Out of 10,105 patients treated with IVT over a period spanning from 1998 to 2017 across the 
participating TRISP centers, information on SaO was missing in 31 (0.3%), yielding a total of 
10,074 patients eligible for analysis (median [IQR] age 73 [62 – 80] years, 44.7% female, 
10.3% IVT followed by EVT).  
Among study patients, 146 (1.5%) had SaO. SaO patients had significantly higher NIHSS 
scores (median [IQR] 13 [7 – 21] vs 9 [5 – 15], p<0.001) and glucose levels on admission 
(median [IQR] 7.1 [6.1 – 8.5] vs 6.6 [5.8 – 8.0], p=0.016), were more often female (54.1% vs 
44.6%, p=0.027), had more often prior stroke (25.7% vs 16.5%, p=0.005) and prior functional 
dependence (16.4% vs 7.6%, p<0.001) and more often final diagnosis of a stroke mimic 
(39% vs 2.1%, p<0.001) than patients without SaO. Patients’ baseline characteristics 
stratified to presence or absence of SaO are summarized in Table 1. 
sICH  
Among SaO patients, 8/146 (5.7%) had sICH compared to 359/9,806 (3.7%) in non-SaO 
patients. After adjustment for the aforementioned outcome-modifying variables, there was no 
difference in the odds for sICH between SaO and non-SaO patients in the logistic model 
(ORadjusted 0.52, 95% CI [0.13, 2.16]). The same was true in the matched (ORmatched 0.68, 
95% CI [0.15, 3.03]) and weighted analysis (ORweighted 0.95, 95% CI [0.39, 2.32]). 
All-cause mortality at 3 months 
At 3 months, 30/146 SaO patients (20.5%) had died compared to 1,432/9,709 non-SaO 
patients (14.8%). After adjustment for confounders, there was no difference in the odds for 3-
month mortality between SaO and non-SaO patients in the logistic model (ORadjusted 0.98, 
95% CI [0.5, 1.92]. This held true in the matched (ORmatched 1.13, 95% CI [0.55, 2.33]) and 
weighted analysis (ORweighted 1.17, 95% CI [0.73, 1.88]). 
Functional outcome on the mRS at 3 months  
At 3 months, 75/146 SaO patients (51.4%) had poor functional outcome (mRS ≥ 3) compared 
to 4,277/9,656 non-SaO patients (44.3%). After adjustment for confounders, the odds for 
poor functional outcome did not differ between SaO and non-SaO patients in the logistic 
model (ORadjusted 0.78, 95% CI [0.45, 1.32]), nor in the matched (ORmatched 0.75, 95% CI 
[0.43, 1.32]) and weighted analysis ORweighted 0.87, 95% CI [0.57, 1.34]). Similarly, when 
examining mRS as an ordinal variable, the adjusted, matched and weighted analyses 
showed no difference in the distribution of the mRS scores between SaO and non-SaO 
patients (ORadjusted 0.78, 95% CI [0.52, 1.16]; ORmatched 0.45, 95% CI [0.10, 2.06]; ORweighted 
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1.00, 95% CI [0.66, 1.52]). Consistent with the main analysis, there was no association 
between SaO and 3-month mRS in the adjusted logistic models after including only survivors.  
Figure 1 shows the odds ratio estimates for sICH, 3-month mortality, poor 3-month functional 
outcome (mRS ≥ 3) and shift to a higher 3-month mRS in patients with versus without SaO in 
the overall study population. The detailed results of the main analysis are presented in Table 
2. The detailed results of the mRS analyses in survivors only are given in Supplemental 
Table 2. Supplemental Table 3 descriptively presents the outcome measures stratified to 
presence or absence of SaO separately in patients treated with IVT alone and those treated 
with IVT followed by EVT. 
Interaction between final diagnosis and prognostic significance of SaO  
Ancillary analyses in the adjusted logistic models revealed no interaction effect between SaO 
and final diagnosis on the outcomes sICH (p = 0.97 for interaction) and 3-month mRS, the 
latter both as a dichotomized (p = 0.72) and as an ordinal variable (p = 0.80) and also after 
including only survivors (p = 0.31 and 0.26 respectively). The ancillary analysis for interaction 
between SaO and final diagnosis was not performed for 3-month mortality because the low 
number of patients with stroke mimics and death did not allow for a stable estimate of the 
interaction term. 
Subgroup analysis in patients with final diagnosis of ischemic stroke 
In the subgroup of 9,612 patients with a final diagnosis of ischemic stroke, sICH occurred in 
5/89 SaO patients (5.6%) and in 345/9,421 non-SaO patients (3.7%). Death at 3 months was 
reported in 28/89 SaO patients (31.5%) compared to 1,388/9,325 non-SaO patients (14.9%). 
Poor 3-month functional outcome was observed in 50/89 SaO patients (56.2%) compared to 
4,160/9,285 non-SaO patients (44.8%). Consistent with the main analysis, the ancillary 
adjusted, matched and weighted analyses revealed no significant differences between SaO 
and non-SaO patients with final diagnosis of ischemic stroke in any of the outcomes. Details 
are given in Supplemental Table 2.  
Clinical and neuroimaging characterization of the SaO patients 
Among the 146 patients with SaO, the seizure had focal onset without impaired awareness in 
14 patients (9.6%), focal onset with impaired awareness in 37 (25.3%) and focal onset with 
evolution to bilateral tonic-clonic seizure or generalized onset in 81 (55%). The SaO had 
occurred before hospital admission in 111 patients (76%), after admission and before IVT in 
18 (12.3%) and during IVT in 17 (11.6%). Acute antiepileptic treatment was administered to 
65 patients (45.8%), and 73 patients (50%) were prescribed long-term antiepileptic treatment. 
Seizures recurred during hospital stay in 28 patients (19.6%). Further details are given in 
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Supplemental Table 4. Most common potentially confounding factors in SaO patients were 
chronic ischemic brain lesions in 30 patients (20.5%) and prior use of antiepileptic drugs 
and/or benzodiazepines in 28 (19.2%). The initial neuroimaging modality was CT in 121 
patients (82.9%), magnetic resonance imaging (MRI) in 21 (14.4%) and both in 4 (2.7%). The 
final diagnosis was stroke mimic in 6/25 (24%) SaO patients that had been initially evaluated 
with MRI (with or without CT) compared to 51/121 (42.1%) SaO patients that were initially 
evaluated with CT alone (p=0.09). The final diagnosis was stroke mimic in 32/106 (30.2%) 
SaO patients that had initially been evaluated with advanced imaging (angiography with or 
without perfusion) compared to 25/40 (62.5%) SaO patients without initial advanced imaging 
(p<0.001). Among SaO patients with a final diagnosis of stroke mimic, 44/57 (77.2%) had a 
clear cause of the seizure (details in Supplemental Table 5).  
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Discussion 
This large, observational, multicenter study on the prognostic impact of seizure at onset in 
patients treated with IVT for assumed ischemic stroke showed the following key findings: (i) 
SaO patients had a more unfavorable baseline risk profile compared to non-SaO patients, 
including higher stroke severity and more often prior stroke and pre-existing dependence. (ii) 
After controlling for confounders, SaO was not an independent predictor for sICH, nor for 
mortality and functional outcome at 3 months. (iii) Results were consistent regardless of 
whether patients were eventually diagnosed with an ischemic stroke or a stroke mimic.  
Whether to use or refrain from IVT in SaO patients is controversial, as there is currently 
hardly any evidence which would allow balancing risks versus benefit of IVT in these 
patients. With this study we provide data indicating that in patients treated with IVT for 
assumed ischemic stroke, functional outcome as well as the odds for complications including 
sICH and mortality are not modified by the presence or absence of SaO. In the absence of 
randomized controlled data on this issue, our results might be clinically important for 
individual treatment decisions.  
Until now, data on SaO patients were included in reports about the prognostic significance of 
early seizures, which were defined as seizures occurring within 7 days30, 72 hours31 and 24 
hours32 after stroke onset, respectively. According to all these reports, early seizures 
indicated a poor prognosis.30-32 However, SaO-patients were only a small minority, 
accounting for 3 out of > 3,000 IVT-treated patients in the ENCHANTED trial30, 1 out of 12 
thrombolyzed stroke patients with an early seizure31 and 7 out of 800 stroke patients 
receiving endovascular therapy32. 
Thus, putting our observations in the context of the aforementioned studies, SaO should be 
distinguished from early seizures, as they seem to differ with regards to prognosis after IVT-
treatment. Interestingly, Rodan et al reported on 3 stroke patients who developed a seizure 
during IVT administration followed by dramatic neurological recovery and postulated that 
seizure was a favorable prognostic sign, possibly arising due to cortical reperfusion or 
hyperperfusion after recanalization of an occluded intracranial artery.33 
In our study, SaO patients had higher NIHSS and blood glucose on admission and more 
often prior stroke and prior functional dependence compared to non-SaO patients, factors 
which are known to be associated with worse prognosis.34-37 Indeed, SaO patients had a 
higher rate of sICH, death and poor functional outcome. However, the fact that SaO did not 
independently predict poor outcome after accounting for these confounders indicates that it 
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should be considered as a marker for an unfavorable risk profile rather than a predictor for 
poor outcome per se. This is in line with previous reports on early post-stroke seizures being 
associated with unfavorable baseline risk factors, including higher stroke severity30, 32, 38-42 
and higher admission blood glucose40, 41. Larger, non-lacunar supratentorial infarcts with 
cortical involvement31, 38, 39, 41-43 and a potential neurotoxic, epileptogenic effect of 
hyperglycemia40, 41 might explain these associations. Furthermore, the higher rate of prior 
stroke and prior functional dependence in SaO patients raises the possibility of post-stroke 
seizures. Indeed, structural post-stroke epilepsy was the most common cause of seizures in 
SaO patients with eventual diagnosis of a stroke mimic.  
Our observation that a final diagnosis of stroke mimic does not modify our key findings 
confirms and refines reports about the relative safety of IVT in patients with stroke mimics, 
including patients with (mostly retrospectively diagnosed) seizures12-15. We observed a lower 
rate of stroke mimics in SaO patients that were initially evaluated with advanced imaging and 
MRI, pointing to the usefulness of these modalities in differentiating stroke from stroke 
mimics.8-11, 44, 45  
As a novelty, we observed that also among IVT-treated patients with an eventual diagnosis of 
ischemic stroke, SaO had no independent impact on prognosis. This is important, as it 
advances the so far limited level of evidence and might therefore increase the strength of the 
currently moderate AHA/ASA recommendation7 for IVT in such patients.  
The strengths of our study involving 9 European stroke centers with long-standing experience 
in IVT include (i) its rigorous statistical methodology, employing 3 distinct methods to control 
for confounders that all yielded consistent results, (ii) its large sample size, which allowed for 
adjustment for several confounding factors and which reduces the risk of spurious findings, 
(iii) the high rate of data completeness, reducing the risk of bias, (iv) the prospective and 
standardized data collection on the outcomes and (v) its multicenter design, indicating a 
certain generalizability of our results, at least within the Caucasian patient population treated 
in experienced stroke centers.  
However, the following potential limitations need to be acknowledged: (i) The TRISP 
collaborative registry is not monitored and outcomes are not adjudicated. (ii) As TRISP 
includes only IVT-treated patients, we did not have a comparison group of patients with SaO 
not treated with IVT. (iii) We do not know in how many SaO patients, otherwise eligible for 
IVT, this treatment was withheld because of the SaO. The fact that our rate of SaO among 
IVT-treated patients (i.e.,1.5%) was lower than that of “seizures in the acute stroke setting” 
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reported elsewhere (i.e., 3.6% among 461 patients), indicates that this might have happened, 
although the definition of seizures in that study was unclear46 and although another study 
using a definition similar to ours reported a lower rate of seizure at presentation (i.e., 0.16% 
among 20,000 ischemic stroke patients).6 (iv) Patients with unwitnessed stroke onset might 
have had an unobserved seizure and might therefore have been misclassified as non-SaO. 
(v) Due to the structure of data retrieval in TRISP, data on the semiology of SaO and history 
of epilepsy had to be added post hoc after review of the patients’ medical charts. 
In conclusion, among patients treated with IVT for suspected ischemic stroke, seizure at 
onset was not an independent predictor of poor prognosis. Withholding IVT from otherwise 
eligible patients with seizure at the onset of an acute stroke syndrome seems unjustified. 
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Figure legends 
Figure 1. Odds ratio estimates with 95% CI for sICH, 3-month mortality, poor 3-month 
functional outcome (mRS ≥ 3) and shift to a higher 3-month mRS in unadjusted logistic 
regression (dashed line), adjusted logistic regression, matched and weighted analyses (solid 
lines) in patients with versus without seizure at onset. 
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Table 1.  Baseline characteristics stratified by seizure at onset 
 
  
 
all patients 
(N = 10,074) 
overall 
missing 
values rate  
seizure at onset  
(N = 146) 
no seizure at 
onset 
(N = 9,928) 
p-value 
age, years, median (IQR) 73 (62 – 80) 0% 71.0 (61 – 79) 73 (62 – 80) 0.185 
sex, female, N (%) 4,507/10,074 (44.7) 0% 79/146 (54.1) 4,428/9,928 (44.6) 0.027 
NIHSS on admission, median (IQR) 9 (5 – 16) 0.4% 13 (7 – 21) 9 (5 – 15) < 0.001 
glucose on admission, mmol/l, median (IQR) 6.6 (5.8 – 8.0) 2.6% 7.1 (6.1 – 8.5) 6.6 (5.8 – 8.0) 0.016 
eGFR on admission, ml/min/ 1.73m2, mean (SD)  73.8 (22.8) 10.0% 75.2 (25.4) 73.8 (22.7) 0.479 
onset-to-treatment time, minutes, median (IQR) 135 (95 – 180) 8.4% 133.5 (93.5 – 179.5) 135 (95 – 180) 0.990 
prior antithrombotic drug treatment, N (%)  2.8%   0.774 
no antithrombotic treatment 5,392/9,789 (55.1)  79/145 (54.5) 5,313/9,644 (55.1)  
antiplatelets 3,951/9,789 (40.4)  61/145 (42.1) 3,890/9,644 (40.3)  
anticoagulants ± antiplatelets 446/9,789 (4.4)  5/145 (3.4) 441/9,644 (4.6)  
IVT followed by EVT, N (%) 1,034/10,074 (10.3) 0% 15/146 (10.3) 1,019/9,928 (10.3) 1.000 
prior stroke, N (%) 1,666/10,011 (16.6) 0.6% 37/144 (25.7) 1,629/9,867 (16.5) 0.005 
hypertension, N (%) 6,866/10,035 (68.4) 0.4% 100/144 (69.4) 6,766/9,891 (68.4) 0.860 
hypercholesterolemia, N (%) 4,100/9,983 (41.1) 0.9% 57/143 (39.9) 4,043/9,840 (41.1) 0.833 
diabetes mellitus, N (%) 1,935/10,029 (19.3) 0.4% 25/145 (17.2) 1,910/9,884 (19.3) 0.600 
atrial fibrillation, N (%) 2,759/9,914 (27.8) 1.6% 32/144 (22.2) 2,727/9,770 (27.9) 0.156 
coronary heart disease, N (%) 1,891/10,004 (18.9) 0.7% 22/145 (15.2) 1,869/9,859 (19.0) 0.294 
prior functional dependence (mRS ≥ 3), N (%) 653/8,448 (7.7) 16.1%* 21/128 (16.4) 632/8,320 (7.6) < 0.001 
early hypodensity on initial CT scan, N (%) 1,298/4,740 (27.4) 53.0%† 22/122 (18.0) 1,276/4,618 (27.6) 0.019 
final diagnosis of stroke mimic, N (%) 259/9,871 (2.6) 2.0% 57/146 (39.0) 202/9,725 (2.1) < 0.001 
* information on prior functional dependence was not collected in the center Heidelberg 
† Some centers predominantly used MRI for initial imaging evaluation. In the centers that used CT, information on early hypodensity was available 
only in a subset of patients (variable added post hoc) 
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Table 2. Results of the main analysis for the association of seizure at onset with outcome 
measures 
A. Outcome measures and unadjusted analysis of their association with seizure at onset 
 
all patients 
(N = 10,074) 
overall 
missing 
values rate 
seizure at 
onset 
(N = 146) 
no seizure at 
onset 
(N = 9,928) 
unadjusted logistic regression 
OR  
[95% CI] 
p-value 
sICH (ECASS-II), N (%) 367/9,952 (3.7) 1.2% 8/146 (5.5) 359/9,806 (3.7) 
1.53 
[0.74, 3.14] 
0.25 
3-month mortality, N (%) 1,462/9,855 (14.8) 2.2% 30/146 (20.5) 1,432/9,709 (14.8) 
1.49 
[1.00, 2.24] 
0.05 
poor 3-month functional 
outcome (dichotomized 
mRS ≥ 3), N (%) 
4,352/9,802 (44.4) 2.7% 75/146 (51.4) 4,277/9,656 (44.3) 
1.33  
[0.96, 1.84] 
0.09 
ordinal 3-month 
mRS, N (%) 
0 1,971/9,802 (20.1) 
“ 
31/146 (21.2) 1,940/9,656 (20.1) 
1.35  
[1.01, 1.81] 
0.04 
1 1,983/9,802 (20.2) 10/146 (6.8)  1,973/9,656 (20.4) 
2 1,496/9,802 (15.3) 30/146 (20.5) 1,466/9,656 (15.2) 
3 1,221/9,802 (12.5) 20/146 (13.7) 1,201/9,656 (12.4) 
4 1,061/9,802 (10.1) 15/146 (10.3) 1,046/9,656 (10.8) 
5 608/9,802 (6.2) 10/146 (6.8) 598/9,656 (6.2) 
6 1,462/9,802 (14.9) 30/146 (20.5) 1,432/9,656 (14.8) 
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B.  Analyses for the association of seizure at onset with the outcome measures accounting for confounders 
 
adjusted logistic regression* matched analysis† weighted analysis‡ 
OR 
[95% CI] 
p-value 
OR  
[95% CI] 
p-value 
OR  
[95% CI] 
p-value 
sICH (ECASS-II) 
0.52 
[0.13, 2.16] 
0.37 
0.68  
[0.15, 3.03] 
0.61 
0.95  
[0.39, 2.32] 
0.97 
3-month mortality 
0.98 
[0.50, 1.92] 
0.95 
1.13  
[0.55, 2.33] 
0.73 
1.17  
[0.73, 1.88] 
0.83 
poor 3-month functional outcome 
(dichotomized mRS ≥ 3) 
0.78 
[0.45, 1.32] 
0.35 
0.75  
[0.43, 1.32] 
0.32 
0.87  
[0.57, 1.34] 
0.83 
ordinal 3-month mRS 
0.78 
[0.52, 1.16] 
0.22 
0.45  
[0.10, 2.06] 
0.3 
1.00  
[0.66, 1.52] 
1.00 
* adjustment for age, sex, NIHSS on admission, prior antithrombotic treatment, glucose and eGFR on admission, EVT in addition to IVT, onset-to-
treatment time, prior dependence and prior stroke 
† matching for age, sex, NIHSS, glucose and eGFR on admission, prior stroke and final diagnosis  
‡ weighting with age, sex, NIHSS on admission, prior antithrombotic treatment, glucose and eGFR on admission, EVT in addition to IVT, onset-to-
treatment time, prior stroke and final diagnosis 
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